literature

HIV mutation literature information.

Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia.

PMID: 31754119 2019 Scientific reports

Discussion: Phylogenetic inference indicated a transmission link with one UK sequence with a similar mutation pattern, PI: V32I, M46L, I47A, V82A + NRTI: T215Y + NNRTI: L100I, K103N.

Antiretroviral Drug Resistance Mutations among HIV Treatment Failure Patients in Tehran, Iran.

PMID: 29026792 2017 Iranian journal of public health

Result: For PIs, G73SC and I47VA were observed as the most common minor and major mutations, respectively.

Discussion: I47VA confers high-level resistance to lopinavir and fosamprenavir; as well low/intermediate-resistance to the remaining PIs expect for atazanaavir and saquinavir.

Discussion: Hence, we recommend more studies to inve

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).

PMID: 28891788 2017 HIV clinical trials

Method: Primary PI-R substitutions assessed were D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, I54L/M, Q58E, T74P, L76V, V82A/F/L/S/T, I84V, N88S, and L90M in PR.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.

PMID: 26717411 2015 PloS one

Table: I47A

Discussion: Our analysis suggests that the four mutations V82A, L76V, I84V, and I47A would have a sensitivity approaching 90% for detecting intermediate or high-level LPV resistance and that I50L and N88S are the most common major PI-associated DRMs to develop in individuals with VF and intermediate or high-level ATV resistance on an initial ATV/r-associated regimen.

Outcome of patients on second line antiretroviral therapy under programmatic condition in India.

PMID: 26572102 2015 BMC infectious diseases

Table: I47A

HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy.

PMID: 26558396 2015 PloS one

Table: I47A

A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.

PMID: 25259833 2014 AIDS (London, England)

Result: Of the 243 patients who received one or more protease inhibitors, 32 (13%) had a study-defined protease inhibitor-resistance mutation most commonly L10F, K20T, V32I, L33F, M46I/L, I47V/A, I50L, F53L, I54V/L, Q58E, L76V, V82A/C, I84V, L89V, and L90M.

2014 Update of the drug resistance mutations in HIV-1.

PMID: 25101529 2014 Topics in antiviral medicine

Discussion: However, there is emerging evidence that specific mutations, most notably I47A (and possibly I47V) and V32I, are associated with high-level resistance.

Characteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, China.

PMID: 24586665 2014 PloS one

Discussion: Results from the HIV-1 drug resistance mutation research by the International AIDS Society-USA (updated in March 2013) have revealed that PI resistance mutation sites are L10I, K20M, V32I, M36I, M46I/L, I47V/A, I50V, Q58E, A71V, G73S, V82A/F/T, I84V, L89V,L90M; NRTIs resistance mutations are M41L, A62V,

PMID: 24093951 2013 Journal of the International AIDS Society

Method: Sequences were analyzed to identify mutations associated with reduced susceptibility to protease and RT inhibitors, as reported by the International AIDS Society-USA in 2010: RT-M41L, A62V, K65R, D67N, 69 insert, K70R, L74V,V75I, F77L, L100I, K101P, K103N, V106A, V106M, V108I, Y115F, F116Y,

Browser Board

Co-occurred Entities

Filtrator